Search company, investor...
Pantec Biosolutions company logo

Pantec Biosolutions

pantec-biosolutions.com

Founded Year

2005

Stage

Unattributed VC | Alive

Total Raised

$19M

Last Raised

$19M | 12 yrs ago

About Pantec Biosolutions

Pantec Biosolutions is a provider of transdermal drug delivery solutions.

Headquarters Location

Industriering 21

9491,

Liechtenstein

Missing: Pantec Biosolutions's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Pantec Biosolutions's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Pantec Biosolutions

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Pantec Biosolutions is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Pantec Biosolutions Patents

Pantec Biosolutions has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/20/2016

11/10/2020

Immunology, Immune system, Clusters of differentiation, Transcription factors, Cytokines

Grant

Application Date

4/20/2016

Grant Date

11/10/2020

Title

Related Topics

Immunology, Immune system, Clusters of differentiation, Transcription factors, Cytokines

Status

Grant

Latest Pantec Biosolutions News

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

Feb 23, 2021

Common immunization routes for coronavirus disease 2019 (COVID-19) vaccine candidates range from intramuscular, nasal and oral to intradermal. Now, scientists at the University of Salzburg and Pantec Biosolutions AG have developed a laser-facilitated epicutaneous immunization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein . The model has induced angiotensin-converting enzyme 2 (ACE2) blocking antibodies in mice. Epicutaneous immunization As the pandemic continues to spread, many countries have already rolled out their immunization plans. To date, there are about 251 vaccines developed against SARS-CoV-2 infection. Of these, 70 vaccines are undergoing human trials to determine safety and efficacy . Most of the COVID-19 vaccines developed are administered intramuscularly, while others can be given orally, intradermally, subcutaneously, and intranasally. Epicutaneous immunization involves the introduction of biological material, drugs, or vaccines into the skin by shallow and bloodless piercing with small needles. Currently, immunization through the skin gained attention as an alternative to traditional vaccine routes such as intramuscular or subcutaneous injections. The researchers developed a generation of skin micropores using infrared laser beams. The method is painless and bloodless, which can overcome the cornified outermost skin barrier and deliver large molecules like biologicals. Related Stories The method has been tested recently in healthy human adults utilizing epicutaneous patches that contain recombinant pertussis toxin. It showed promise to stimulate recall antibody responses, which was akin to the response induced by an injection of a commercial diphtheria-tetanus-acellular pertussis vaccine adjuvanted with alum. The study In the study, the researchers investigated whether laser-facilitated epicutaneous immunization with recombinant SARS-CoV-2 S1 spike protein could stimulate antibody responses that can prevent the spike from binding with the human cell ACE2 receptor. For adjuvant action, the researchers used LT-B and CpG, which are known to be the most effective in inducing immune responses after epicutaneous immunization. The mice immunized with the SARS-CoV-2 spike S1 protein exhibited high titers of specific blood immunoglobulin G (IgG) in two independent experiments. The LT-B markedly elevated IgG levels. Meanwhile, the mice vaccinated with CpG-ODN 1826 adjuvant manifested the highest antibody titers of all the clusters. When the team increased the interval between vaccinations, there is no significant effect on the level of antibody response. Further, the CpG induced a faster immune response. The titers can be boosted 5-fold when using the LT-B and more than 10-fold by CpG-ODN 1826. The serum antibodies produced can inhibit the interaction between the spike protein and the ACE2 human receptor. After testing the skin immunization method with certain adjuvants, like the LT-B, it promoted mucosal immune responses. This shows that skin-based immunization with SARS-CoV-2 spike S1 protein can also stimulate antibody responses in the respiratory tract, the site primarily targeted by SARS-CoV-2. Apart from inducing ACE2 inhibitory antibodies, laser-assisted epicutaneous immunization prompted spike-specific T-helper cells, which could cause long-term memory responses. This means that the vaccine can protect against SARS-CoV-2 for long periods, reducing the risk of re-infection. To date, there are more than 111.75 million cases of COVID-19 globally. Of these, 2.47 million have died. *Important Notice bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information. Sources: COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) - https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 World Health Organization (WHO). (2021). Draft landscape and tracker of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines Journal reference: Scheiblhofer, S., Drother, S., Braun, W., Braun, R., Boesch, M., and Weiss, R. (2021). Laser-facilitated epicutaneous immunization with SARS-CoV-2 spike protein induces ACE2 blocking antibodies in mice. bioRxiv. doi: https://doi.org/10.1101/2021.02.22.432259 , https://www.biorxiv.org/content/10.1101/2021.02.22.432259v1

Pantec Biosolutions Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Pantec Biosolutions Rank

Pantec Biosolutions Frequently Asked Questions (FAQ)

  • When was Pantec Biosolutions founded?

    Pantec Biosolutions was founded in 2005.

  • What is Pantec Biosolutions's latest funding round?

    Pantec Biosolutions's latest funding round is Unattributed VC.

  • How much did Pantec Biosolutions raise?

    Pantec Biosolutions raised a total of $19M.

  • Who are the investors of Pantec Biosolutions?

    Investors of Pantec Biosolutions include StemCell Holding AG, Gamma Capital Partners, DJD Partners Trust and Pantec Engineering.

  • Who are Pantec Biosolutions's competitors?

    Competitors of Pantec Biosolutions include Valeritas, Corium International, Sagent Pharmaceuticals, Vapore, Catalent and 13 more.

Compare Pantec Biosolutions to Competitors

P
PharmaJet

PharmaJet develops and commercializes a needle-free platform to administer drugs and biologics. It offers two needle-free systems, Tropis ID for 0.1 ml intradermal injections and Stratis IM/SC for 0.5 ml intramuscular and subcutaneous injections. The company was founded in 2005 and is based in Golden, Colorado.

A
Aegis Biosciences

Aegis Biosciences is a developer of biomaterial drug delivery and wound healing technologies.

M
Medlogics

Medlogics is an early stage medical device company developing a broad platform technology for drug delivery. The initial focus is product development of polymer-free stent drug delivery.

R
Replenish

Replenish Inc is a Pasadena, Calif.-based developer of a drug delivery platform.

A
AerovectRx

AerovectRx is an aerosol therapeutic company providing effective and dosage-controlled drug delivery using the respiratory system as the gateway for better health. Products under development by AerovectRx are designed to deliver a wide variety of therapies through multiple-use mass immunization as well as personal-use nebulizers. Potential targeted therapeutic candidates for the AerovectRx technology include treatments for asthma, cystic fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), diabetes, pain management, and for delivery of vaccines and anti-viral drugs.

D
Depotech

Depotech is developing methods for drug delivery

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.